No Data
No Data
Bluebird Bio Announces Completion of Its Q2 2024 Form 10-Q Filing
bluebird bio | 10-Q: Quarterly report
Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Analyst Ratings
No Data
No Data
105482297 OP : yes it's about time